| ［1］ |
中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000.
|
| ［2］ |
Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis［J］. J Am Acad Dermatol, 2014,70（2）:338⁃351. doi: 10.1016/j.jaad.2013.10.010.
|
| ［3］ |
Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema （atopic dermatitis） part II［J］. J Eur Acad Dermatol Venereol, 2012,26（9）:1176⁃1193. doi: 10.1111/j.1468⁃3083.2012.04636.x.
|
| ［4］ |
Ahn K, Kim BE, Kim J, et al. Recent advances in atopic dermatitis［J］. Curr Opin Immunol, 2020,66:14⁃21. doi: 10.1016/j.coi.2020.02.007.
|
| ［5］ |
Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS［J］. J Am Acad Dermatol, 2020,82（6）:1328⁃1336. doi: 10.1016/j.jaad.2020.02.060.
|
| ［6］ |
Beck LA, Thaçi D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open⁃label study of adults with moderate⁃to⁃severe atopic dermatitis［J］. Am J Clin Dermatol, 2020,21（4）:567⁃577. doi: 10.1007/s40257⁃020⁃00527⁃x.
|
| ［7］ |
de Bruin⁃Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo⁃controlled, randomized phase III clinical trial （LIBERTY AD CAFÉ）［J］. Br J Dermatol, 2018,178（5）:1083⁃1101. doi: 10.1111/bjd.16156.
|
| ［8］ |
Wang C, Kraus CN, Patel KG, et al. Real⁃world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients′ records［J］. Int J Dermatol, 2020,59（2）:253⁃256. doi: 10.1111/ijd.14573.
|
| ［9］ |
Wollenberg A, Howell MD, Guttman⁃Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti⁃IL⁃13 mAb［J］. J Allergy Clin Immunol, 2019,143（1）:135⁃141. doi: 10.1016/j.jaci. 2018.05.029.
|
| ［10］ |
Pavel AB, Song T, Kim HJ, et al. Oral Janus kinase/SYK inhibition （ASN002） suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2019,144（4）:1011⁃1024. doi: 10.1016/j.jaci.2019.07.013.
|
| ［11］ |
Bissonnette R, Maari C, Forman S, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate⁃to⁃severe atopic dermatitis: results from a randomized double⁃blind placebo⁃controlled study［J］. Br J Dermatol, 2019,181（4）:733⁃742. doi: 10.1111/bjd.17932.
|
| ［12］ |
Silverberg JI, Tallman AM, Ports WC, et al. Evaluating the efficacy of crisaborole using the atopic dermatitis severity index and percentage of affected body surface area［J］. Acta Derm Venereol, 2020,100（13）:adv00170. doi: 10.2340/00015555⁃3489.
|
| ［13］ |
Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream （JAK1/JAK2 inhibitor） or triamcinolone cream［J］. J Allergy Clin Immunol, 2020,145（2）:572⁃582. doi: 10.1016/j.jaci.2019.08.042.
|
| ［14］ |
Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis［J］. Sci Transl Med, 2017,9（378）:eaah4680. doi: 10.1126/scitranslmed.aah4680.
|
| ［15］ |
Yoo J, Choi JY, Lee BY, et al. Therapeutic effects of saline groundwater solution baths on atopic dermatitis: a pilot study［J］. Evid Based Complement Alternat Med, 2020,2020:8303716. doi: 10.1155/2020/8303716.
|
| ［16］ |
Maarouf M, Shi VY. Bleach for atopic dermatitis［J］. Dermatitis, 2018,29（3）:120⁃126. doi: 10.1097/DER.0000000000000358.
|
| ［17］ |
Fishbein AB, Lor J, Penedo FJ, et al. Patient⁃reported outcomes for measuring sleep disturbance in pediatric atopic dermatitis: cross sectional study of PROMIS pediatric sleep measures and actigraphy［J］. J Am Acad Dermatol, 2020,S0190⁃9622（20）31015⁃X. doi: 10.1016/j.jaad. 2020.05.138.
|
| ［18］ |
Gustafson CJ, O′Neill J, Hix E, et al. Feasibility of actigraphy wristband monitoring of atopic dermatitis in children［J］. Skin Res Technol, 2014,20（4）:510⁃514. doi: 10.1111/srt.12147.
|
| ［19］ |
Dong B, Ren A, Shah SA, et al. Monitoring of atopic dermatitis using leaky coaxial cable［J］. Healthc Technol Lett, 2017,4（6）:244⁃248. doi: 10.1049/htl.2017.0021.
|
| ［20］ |
Eto H, Tsuji G, Chiba T, et al. Non⁃invasive evaluation of atopic dermatitis based on redox status using in vivo dynamic nuclear polarization magnetic resonance imaging［J］. Free Radic Biol Med, 2017,103:209⁃215. doi: 10.1016/j.freeradbiomed.2016.12. 043.
|
| ［21］ |
Wenninger K, Kehrt R, von Rüden U, et al. Structured parent education in the management of childhood atopic dermatitis: the Berlin model［J］. Patient Educ Couns, 2000,40（3）:253⁃261. doi: 10.1016/s0738⁃3991（99）00074⁃9.
|
| ［22］ |
van Os⁃Medendorp H, Deprez E, Maes N, et al. The role of the nurse in the care and management of patients with atopic dermatitis［J］. BMC Nurs, 2020,19（1）:102. doi: 10.1186/s12912⁃020⁃00494⁃y.
|
| ［23］ |
赖沙, 王华. 特应性皮炎治疗中的患者教育和管理［J］. 国际皮肤性病学杂志, 2013,39（4）:255⁃257. doi: 10.3760/cma.j.issn. 1673⁃4173.2013.04.014.
|
| ［24］ |
蒲晓英. 全程健康教育对银屑病患者生活质量的影响［J］. 中国医疗前沿, 2013,（10）:110⁃111. doi: 10.3969/j.issn.1673⁃5552. 2013.10.0082.
|
